GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
GLP-1 單一、雙重及三重受體激動劑在治療第二型糖尿病和肥胖症中的應用:敘述性回顧。
EClinicalMedicine 2024-09-16
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
口服胰高血糖素樣肽-1受體激動劑及腸胰激素組合物作為治療成人2型糖尿病的現況何在?
Expert Opin Pharmacother 2024-05-22
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
腸道激素多激動劑用於治療第2型糖尿病和肥胖:進展與挑戰。
J Endocrinol 2024-06-25
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.
肥胖症和第二型糖尿病藥物治療的新發展 - GLP-1 受體激動劑的範疇內和範疇外。
Biomedicines 2024-06-27
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19